Attralus Closes $56 Million Financing
Summary
- Proceeds intended to advance clinical pipeline of transformational pan-amyloid removal (PAR) therapeutic candidates- Financing led by Alpha Wave Global and also included Bristol Myers Squibb (BMY)SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical-stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that it has closed a $56 million financing. The financing proceeds are also expected to support the clinical development of the pan-amyloid diagnostic imaging agent I-124-Evuzamitide (AT-01) and AT-05 as well as the preclinical development of PAR therapeutic candidates for the treatment of neurodegenerative diseases.We are thrilled to support Attralus in its vision to build a leading Systemic Amyloidosis company and the companys approach of targeting removal of existing amyloid deposits, going beyond current treatments that slow progression but do not remove amyloid from organs said Chris Dimitropoulos, Managing Director of Healthcare Investments at Alpha Wave Global. In clinical trials, I-124-Evuzamitide has been shown to detect multiple types of amyloid deposits, including AL and ATTR, in major organs such as the heart, kidney, liver, and spleen. Attralus has a special protocol assessment (SPA) in place with the FDA to conduct a single pivotal Phase 3 trial for I-124-Evuzamitide.About AT-05, Pan-Amyloid DiagnosticAT-05, uses the same pan amyloid binding peptide as I-124 -Evuzamitide but is labelled with technetium-99m (Tc-99m, 99mTc). Its flagship global private equity fund, Alpha Wave Ventures, aims to invest in best-in-class growth-stage companies and endeavors to be helpful long-term partners to the founders and management teams.